MX2023013711A - Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae. - Google Patents
Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae.Info
- Publication number
- MX2023013711A MX2023013711A MX2023013711A MX2023013711A MX2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A
- Authority
- MX
- Mexico
- Prior art keywords
- enavogliflozin
- animal
- pharmaceutical composition
- diabetes mellitus
- treating diabetes
- Prior art date
Links
- KORCWPOBTZTAFI-YVTYUBGGSA-N (2s,3r,4r,5s,6r)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC(CC=2C=CC(=CC=2)C2CC2)=C(Cl)C2=C1CCO2 KORCWPOBTZTAFI-YVTYUBGGSA-N 0.000 title abstract 3
- 241000282421 Canidae Species 0.000 title abstract 3
- 241001465754 Metazoa Species 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 229940012775 enavogliflozin Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica para la prevención o tratamiento de la diabetes mellitus en un animal de la familia Canidae, que incluye como principio activo la enavogliflozina. La composición farmacéutica de la presente invención, que incluye enavogliflozina como un ingrediente activo, muestra un excelente efecto de control del nivel de glucosa en sangre y, por lo tanto, puede usarse de manera efectiva para tratar la diabetes mellitus en un animal de la familia Canidae.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210065733 | 2021-05-21 | ||
| PCT/KR2022/007206 WO2022245171A1 (ko) | 2021-05-21 | 2022-05-20 | 이나보글리플로진을 포함하는 개과 동물의 당뇨병 예방 또는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013711A true MX2023013711A (es) | 2024-01-16 |
Family
ID=84141513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013711A MX2023013711A (es) | 2021-05-21 | 2022-05-20 | Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245641A1 (es) |
| EP (1) | EP4342476A1 (es) |
| JP (1) | JP2024518644A (es) |
| KR (1) | KR20220157906A (es) |
| CN (1) | CN117460517A (es) |
| AU (1) | AU2022276995A1 (es) |
| BR (1) | BR112023024125A2 (es) |
| CA (1) | CA3219572A1 (es) |
| MX (1) | MX2023013711A (es) |
| WO (1) | WO2022245171A1 (es) |
| ZA (1) | ZA202310748B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240107660A (ko) * | 2022-12-30 | 2024-07-09 | 주식회사 대웅제약 | 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110117841A (ko) * | 2010-04-22 | 2011-10-28 | 황우석 | Ｐｅｐｃｋ 과발현 형질전환 복제 개과 동물 및 이의 생산방법 |
| CN103180435A (zh) * | 2010-08-31 | 2013-06-26 | 库克通用生物技术有限责任公司 | 用于治疗动物疾病的全身的同种异体干细胞疗法 |
| ES2719656T3 (es) | 2011-06-01 | 2019-07-11 | Green Cross Corp | Derivados de difenilmetano novedosos como inhibidores del SGLT2 |
| KR20220097538A (ko) * | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
| JP6682621B2 (ja) * | 2015-08-27 | 2020-04-15 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | Ｓｇｌｔ−２阻害剤含む液体医薬組成物 |
-
2022
- 2022-05-20 KR KR1020220061797A patent/KR20220157906A/ko unknown
- 2022-05-20 EP EP22805024.1A patent/EP4342476A1/en active Pending
- 2022-05-20 CN CN202280036648.7A patent/CN117460517A/zh active Pending
- 2022-05-20 US US18/562,428 patent/US20240245641A1/en active Pending
- 2022-05-20 JP JP2023572193A patent/JP2024518644A/ja active Pending
- 2022-05-20 WO PCT/KR2022/007206 patent/WO2022245171A1/ko active Application Filing
- 2022-05-20 MX MX2023013711A patent/MX2023013711A/es unknown
- 2022-05-20 AU AU2022276995A patent/AU2022276995A1/en active Pending
- 2022-05-20 CA CA3219572A patent/CA3219572A1/en active Pending
- 2022-05-20 BR BR112023024125A patent/BR112023024125A2/pt unknown
-
2023
- 2023-11-21 ZA ZA2023/10748A patent/ZA202310748B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3219572A1 (en) | 2022-11-24 |
| ZA202310748B (en) | 2024-07-31 |
| BR112023024125A2 (pt) | 2024-01-30 |
| US20240245641A1 (en) | 2024-07-25 |
| CN117460517A (zh) | 2024-01-26 |
| WO2022245171A1 (ko) | 2022-11-24 |
| JP2024518644A (ja) | 2024-05-01 |
| KR20220157906A (ko) | 2022-11-29 |
| EP4342476A1 (en) | 2024-03-27 |
| AU2022276995A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501009A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
| ZA202310748B (en) | Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin | |
| NZ701559A (en) | Compositions comprising povidone-iodine | |
| BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
| MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| GB2476202A (en) | Novel choline cocrystal of epalrestat | |
| WO2011049327A3 (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| WO2018169282A3 (ko) | Atpif1을 함유하는 당뇨 치료용 약학조성물 | |
| MX2022014309A (es) | Compuestos de insulina acilada de accion temporal prolongada. | |
| WO2021046315A3 (en) | Inhibitors of encephalitic alphaviruses | |
| MX2023007080A (es) | Metodo para el tratamiento de la fibrosis. | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| EA200800338A1 (ru) | Профилактика и лечение офтальмологических осложнений диабета | |
| HK1109563A1 (en) | Protein hydrolysate with antidiabetic effect | |
| WO2020016655A3 (en) | Treatment of neuropathy with dna constructs expressing igf-1 isoforms | |
| MY197721A (en) | Composition and uses thereof | |
| WO2010044637A3 (ko) | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 | |
| BR112022004038A2 (pt) | Composições veterinárias granulares palatáveis | |
| WO2019035646A8 (ko) | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 | |
| MX2014001855A (es) | Nuevo compuesto aislado de quamoclit, y una composicion para la prevencion o el tratamiento de la diabetes que contiene el compuesto como un ingrediente activo. | |
| EP4327815A3 (en) | Probiotics for regulating blood glucose | |
| ATE529127T1 (de) | Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung | |
| WO2020018058A3 (en) | The injectable micronized human insulin |